ESMO World Congress on Gastrointestinal Cancer 2022

Barcelona, Spain 29 June 2022 - 02 July 2022

Tucatinib-trastuzumab combo induces durable tumour response in HER2+ mCRC

19 Sep 2022 by

Dual HER-2 inhibition with tucatinib and trastuzumab induces clinically meaningful and durable responses in patients with previously treated metastatic HER2-positive colorectal cancer (mCRC) in the phase II MOUNTAINEER trial, boosting hopes for this chemotherapy-free combination.

Tucatinib-trastuzumab combo induces durable tumour response in HER2+ mCRC

19 Sep 2022

Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?

14 Sep 2022 by

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?

14 Sep 2022

Pembrolizumab shows durable efficacy in sorafenib-treated advanced HCC

14 Sep 2022 by

Pembrolizumab has demonstrated durable efficacy and a manageable adverse event (AE) profile in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib in a 5-year follow-up of the KEYNOTE-224 study.

Pembrolizumab shows durable efficacy in sorafenib-treated advanced HCC

14 Sep 2022

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function

11 Sep 2022 by

The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function

11 Sep 2022

Second-line NIVO + IPI combo sustains response, OS benefit in aHCC

30 Aug 2022 by

The combination of nivolumab 1 mg/kg (NIVO1) and ipilimumab 3 mg/kg (IPI3) every 3 weeks followed by NIVO 240 mg every 2 weeks in the second-line setting continues to confer durable response and overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (aHCC), according to 5-year data from the CheckMate 040* trial presented at ESMO GI 2022.

Second-line NIVO + IPI combo sustains response, OS benefit in aHCC

30 Aug 2022

Durvalumab + gemcitabine-cisplatin benefit in biliary tract cancer consistent across tumour locations

27 Aug 2022 by

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.

Durvalumab + gemcitabine-cisplatin benefit in biliary tract cancer consistent across tumour locations

27 Aug 2022

First-line tislelizumab + chemo improves OS in advanced/metastatic ESCC

23 Aug 2022 by

First-line treatment with tislelizumab + chemotherapy significantly improves overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy alone, according to an interim analysis of the RATIONALE-306* trial presented at ESMO GI 2022.

First-line tislelizumab + chemo improves OS in advanced/metastatic ESCC

23 Aug 2022

RATIONALE-208 subanalyses boost tislelizumab potential for HCC

05 Aug 2022 by

The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.

RATIONALE-208 subanalyses boost tislelizumab potential for HCC

05 Aug 2022

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

03 Aug 2022 by

The addition of erlotinib to best supportive care (BSC) provided better survival benefit than BSC only in individuals with unresectable/metastatic gall bladder cancer (GBC) with poor performance status (PS), according to a phase II/III open-label study.

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

03 Aug 2022